PARP-targeted radiotherapy offers the exciting prospect of delivering cytotoxic radiation directly to the tumor cell nucleus, and therefore, the DNA, instead of the cell membrane or tumor microenvironment, raising hopes to more efficiently introduce DNA damage compared to extranuclear radioligand therapy agents. Here, PARP1 is linked to neoplasm.